Clinical Trial Update: A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing SKB264 to investigator's choice chemotherapy in unresectable recurrent or metastatic triple-negative breast cancer is currently recrui…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• SKB264

Snippet

Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Conditions: Triple Negative Breast Cancer | Phase 3 | Status: RECRUITING